COMPANY PROFILE

Starna Therapeutics

Explore full profile

A company developing tissue selective targeted RNA therapies for unmet patient needs

Suzhou Shi, ChinaFounded 2021Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Starna Therapeutics

Starnatx specializes in nucleic acid drug discovery and delivery technology, focusing on RNA-based therapies. The company operates in the biotechnology sector, serving pharmaceutical companies and research institutions. Starnatx leverages its proprietary STARSelective Targeted RNA Delivery LNP technology platform to deliver RNA-based treatments to specific organs, tissues, and individual cell types, such as T cells. This targeted approach addresses key challenges in RNA drug research and development, enhancing the precision and efficacy of treatments. The business model revolves around partnerships and collaborations with pharmaceutical firms, generating revenue through licensing agreements and service contracts. Starnatx's comprehensive industrial chain includes chemistry, mRNA, and LNP preparations, ensuring a robust and scalable production process.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Suzhou Shi, China
Employees: 4
Open positions: None listed
Dealroom signal: 57.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	May 2026	$40M	$400M	Lilly Asia Ventures · Source Code Capital · Primavera Capital Group · LYFE Capital	↗
SERIES BOther financing	Oct 2025	—	—	Source Code Capital · Lilly Asia Ventures	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Starna Therapeutics website traffic

Latest recorded traffic for Starna Therapeutics is 1K monthly website visits, up 28.2% over the last three months. Starna Therapeutics's team grew 0% over the past year.

Latest monthly visits1K 3-month web change+28.2% 1-year team growth0%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VOVodorasloYour solution to better air quality	Sofia, Bulgaria	Operational	1	$61K	$132K
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
RPRivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health	Charlottesville, United States	Operational
KTKintsugi TherapeuticsDevelopment of ER stress inhibitors for the treatment of metabolic diseases	Barcelona, Spain	Operational